$WANBURY

WANBURY: USFDA CLEARS MULTIPLE ANDAs WITH NO DMF DEFICIENCY LETTER 🇺🇸💊 • ✅ Wanbury has received "No DMF Deficiency Letter" from the USFDA for multiple ANDAs using its Metformin HCl API across different formulations • 🌍 The development strengthens the regulatory acceptance of Wanbury's Metformin API in the US market • 🇰🇷 The company also highlighted expansion of business opportunities in South Korea through filing of a DMF for another API • 🚀 Wanbury reiterated its commitment to supplying high-quality APIs to new international markets 🟢 Impact: Positive (USFDA regulatory clearance supports exports, enhances credibility, and can improve opportunities for API supplies to global generic drug manufacturers.)